Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.

Schepetkin IA, Karpenko AS, Khlebnikov AI, Shibinska MO, Levandovskiy IA, Kirpotina LN, Danilenko NV, Quinn MT.

Eur J Med Chem. 2019 Dec 1;183:111719. doi: 10.1016/j.ejmech.2019.111719. Epub 2019 Sep 18.

PMID:
31563013
2.

The investigation of structure-activity relationship of polyamine-targeted synthetic compounds from different chemical groups.

Syatkin SP, Neborak EV, Khlebnikov AI, Komarova MV, Shevkun NA, Kravtsov EG, Blagonravov ML, Agostinelli E.

Amino Acids. 2019 Sep 13. doi: 10.1007/s00726-019-02778-3. [Epub ahead of print]

PMID:
31520286
3.

Neutrophil Immunomodulatory Activity of Natural Organosulfur Compounds.

Schepetkin IA, Kirpotina LN, Khlebnikov AI, Balasubramanian N, Quinn MT.

Molecules. 2019 May 10;24(9). pii: E1809. doi: 10.3390/molecules24091809.

4.

Protective Effects of a New C-Jun N-terminal Kinase Inhibitor in the Model of Global Cerebral Ischemia in Rats.

Plotnikov MB, Chernysheva GA, Aliev OI, Smol'iakova VI, Fomina TI, Osipenko AN, Rydchenko VS, Anfinogenova YJ, Khlebnikov AI, Schepetkin IA, Atochin DN.

Molecules. 2019 May 3;24(9). pii: E1722. doi: 10.3390/molecules24091722.

5.

Further modifications of 1H-pyrrolo[2,3-b]pyridine derivatives as inhibitors of human neutrophil elastase.

Giovannoni MP, Cantini N, Crocetti L, Guerrini G, Iacovone A, Schepetkin IA, Vergelli C, Khlebnikov AI, Quinn MT.

Drug Dev Res. 2019 Aug;80(5):617-628. doi: 10.1002/ddr.21539. Epub 2019 Apr 19.

PMID:
31002441
6.

Inhibition of T Cell Receptor Activation by Semi-Synthetic Sesquiterpene Lactone Derivatives and Molecular Modeling of Their Interaction with Glutathione and Tyrosine Kinase ZAP-70.

Khlebnikov AI, Schepetkin IA, Kishkentaeva AS, Shaimerdenova ZR, Atazhanova GA, Adekenov SM, Kirpotina LN, Quinn MT.

Molecules. 2019 Jan 19;24(2). pii: E350. doi: 10.3390/molecules24020350.

7.

1H-pyrrolo[2,3-b]pyridine: A new scaffold for human neutrophil elastase (HNE) inhibitors.

Crocetti L, Giovannoni MP, Schepetkin IA, Quinn MT, Khlebnikov AI, Cantini N, Guerrini G, Iacovone A, Teodori E, Vergelli C.

Bioorg Med Chem. 2018 Nov 15;26(21):5583-5595. doi: 10.1016/j.bmc.2018.09.034. Epub 2018 Sep 27.

PMID:
30385225
8.

Synthesis, biological evaluation, and molecular modeling of 11H-indeno[1,2-b]quinoxalin-11-one derivatives and tryptanthrin-6-oxime as c-Jun N-terminal kinase inhibitors.

Schepetkin IA, Khlebnikov AI, Potapov AS, Kovrizhina AR, Matveevskaya VV, Belyanin ML, Atochin DN, Zanoza SO, Gaidarzhy NM, Lyakhov SA, Kirpotina LN, Quinn MT.

Eur J Med Chem. 2019 Jan 1;161:179-191. doi: 10.1016/j.ejmech.2018.10.023. Epub 2018 Oct 12.

PMID:
30347329
9.

Synthesis and analytical characterization of new thiazol-2-(3H)-ones as human neutrophil elastase (HNE) inhibitors.

Crocetti L, Bartolucci G, Cilibrizzi A, Giovannoni MP, Guerrini G, Iacovone A, Menicatti M, Schepetkin IA, Khlebnikov AI, Quinn MT, Vergelli C.

Chem Cent J. 2017 Dec 6;11(1):127. doi: 10.1186/s13065-017-0358-1.

10.

4-Aroyl-3-hydroxy-5-phenyl-1H-pyrrol-2(5H)-ones as N-formyl peptide receptor 1 (FPR1) antagonists.

Kirpotina LN, Schepetkin IA, Khlebnikov AI, Ruban OI, Ge Y, Ye RD, Kominsky DJ, Quinn MT.

Biochem Pharmacol. 2017 Oct 15;142:120-132. doi: 10.1016/j.bcp.2017.07.004. Epub 2017 Jul 8.

11.

Isoxazol-5(2H)-one: a new scaffold for potent human neutrophil elastase (HNE) inhibitors.

Vergelli C, Schepetkin IA, Crocetti L, Iacovone A, Giovannoni MP, Guerrini G, Khlebnikov AI, Ciattini S, Ciciani G, Quinn MT.

J Enzyme Inhib Med Chem. 2017 Dec;32(1):821-831. doi: 10.1080/14756366.2017.1326915.

12.

Chemical composition and phagocyte immunomodulatory activity of Ferula iliensis essential oils.

Özek G, Schepetkin IA, Utegenova GA, Kirpotina LN, Andrei SR, Özek T, Başer KHC, Abidkulova KT, Kushnarenko SV, Khlebnikov AI, Damron DS, Quinn MT.

J Leukoc Biol. 2017 Jun;101(6):1361-1371. doi: 10.1189/jlb.3A1216-518RR. Epub 2017 Mar 3.

13.

Modulation of Human Neutrophil Responses by the Essential Oils from Ferula akitschkensis and Their Constituents.

Schepetkin IA, Kushnarenko SV, Özek G, Kirpotina LN, Sinharoy P, Utegenova GA, Abidkulova KT, Özek T, Başer KH, Kovrizhina AR, Khlebnikov AI, Damron DS, Quinn MT.

J Agric Food Chem. 2016 Sep 28;64(38):7156-70. doi: 10.1021/acs.jafc.6b03205. Epub 2016 Sep 13.

14.

Synthesis and Pharmacological Evaluation of Indole Derivatives as Deaza Analogues of Potent Human Neutrophil Elastase Inhibitors.

Crocetti L, Schepetkin IA, Ciciani G, Giovannoni MP, Guerrini G, Iacovone A, Khlebnikov AI, Kirpotina LN, Quinn MT, Vergelli C.

Drug Dev Res. 2016 Sep;77(6):285-99. doi: 10.1002/ddr.21323. Epub 2016 Jul 30.

15.

2-Arylacetamido-4-phenylamino-5-substituted pyridazinones as formyl peptide receptors agonists.

Vergelli C, Schepetkin IA, Ciciani G, Cilibrizzi A, Crocetti L, Giovannoni MP, Guerrini G, Iacovone A, Kirpotina LN, Khlebnikov AI, Ye RD, Quinn MT.

Bioorg Med Chem. 2016 Apr 8. pii: S0968-0896(16)30253-X. doi: 10.1016/j.bmc.2016.04.019. [Epub ahead of print]

16.

A novel dual NO-donating oxime and c-Jun N-terminal kinase inhibitor protects against cerebral ischemia-reperfusion injury in mice.

Atochin DN, Schepetkin IA, Khlebnikov AI, Seledtsov VI, Swanson H, Quinn MT, Huang PL.

Neurosci Lett. 2016 Apr 8;618:45-49. doi: 10.1016/j.neulet.2016.02.033. Epub 2016 Feb 26.

17.

Antagonism of human formyl peptide receptor 1 with natural compounds and their synthetic derivatives.

Schepetkin IA, Khlebnikov AI, Kirpotina LN, Quinn MT.

Int Immunopharmacol. 2016 Aug;37:43-58. doi: 10.1016/j.intimp.2015.08.036. Epub 2015 Sep 15. Review.

18.

Cinnoline derivatives as human neutrophil elastase inhibitors.

Giovannoni MP, Schepetkin IA, Crocetti L, Ciciani G, Cilibrizzi A, Guerrini G, Khlebnikov AI, Quinn MT, Vergelli C.

J Enzyme Inhib Med Chem. 2016 Aug;31(4):628-39. doi: 10.3109/14756366.2015.1057718. Epub 2015 Jul 21.

19.

Anti-Inflammatory Effects and Joint Protection in Collagen-Induced Arthritis after Treatment with IQ-1S, a Selective c-Jun N-Terminal Kinase Inhibitor.

Schepetkin IA, Kirpotina LN, Hammaker D, Kochetkova I, Khlebnikov AI, Lyakhov SA, Firestein GS, Quinn MT.

J Pharmacol Exp Ther. 2015 Jun;353(3):505-16. doi: 10.1124/jpet.114.220251. Epub 2015 Mar 17.

20.

Novel 3-(1H-indol-3-yl)-2-[3-(4-methoxyphenyl)ureido]propanamides as selective agonists of human formyl-peptide receptor 2.

Lacivita E, Schepetkin IA, Stama ML, Kirpotina LN, Colabufo NA, Perrone R, Khlebnikov AI, Quinn MT, Leopoldo M.

Bioorg Med Chem. 2015 Jul 15;23(14):3913-24. doi: 10.1016/j.bmc.2014.12.007. Epub 2014 Dec 13.

21.

Facile synthesis of pyrazole- and benzotriazole-containing selenoethers.

Potapov AS, Chernova NP, Ogorodnikov VD, Petrenko TV, Khlebnikov AI.

ScientificWorldJournal. 2014;2014:578762. doi: 10.1155/2014/578762. Epub 2014 Nov 20.

22.

Antagonism of human formyl peptide receptor 1 (FPR1) by chromones and related isoflavones.

Schepetkin IA, Kirpotina LN, Khlebnikov AI, Cheng N, Ye RD, Quinn MT.

Biochem Pharmacol. 2014 Dec 15;92(4):627-41. doi: 10.1016/j.bcp.2014.09.027. Epub 2014 Oct 17.

23.

Development of small molecule non-peptide formyl peptide receptor (FPR) ligands and molecular modeling of their recognition.

Schepetkin IA, Khlebnikov AI, Giovannoni MP, Kirpotina LN, Cilibrizzi A, Quinn MT.

Curr Med Chem. 2014;21(13):1478-504. Review.

24.

Optimization of N-benzoylindazole derivatives as inhibitors of human neutrophil elastase.

Crocetti L, Schepetkin IA, Cilibrizzi A, Graziano A, Vergelli C, Giomi D, Khlebnikov AI, Quinn MT, Giovannoni MP.

J Med Chem. 2013 Aug 8;56(15):6259-72. doi: 10.1021/jm400742j. Epub 2013 Jul 25.

25.

Further studies on 2-arylacetamide pyridazin-3(2H)-ones: design, synthesis and evaluation of 4,6-disubstituted analogs as formyl peptide receptors (FPRs) agonists.

Giovannoni MP, Schepetkin IA, Cilibrizzi A, Crocetti L, Khlebnikov AI, Dahlgren C, Graziano A, Dal Piaz V, Kirpotina LN, Zerbinati S, Vergelli C, Quinn MT.

Eur J Med Chem. 2013 Jun;64:512-28. doi: 10.1016/j.ejmech.2013.03.066. Epub 2013 Apr 8.

26.

3-(1H-indol-3-yl)-2-[3-(4-nitrophenyl)ureido]propanamide enantiomers with human formyl-peptide receptor agonist activity: molecular modeling of chiral recognition by FPR2.

Schepetkin IA, Kirpotina LN, Khlebnikov AI, Leopoldo M, Lucente E, Lacivita E, De Giorgio P, Quinn MT.

Biochem Pharmacol. 2013 Feb 1;85(3):404-16. doi: 10.1016/j.bcp.2012.11.015. Epub 2012 Dec 3.

27.

Synthesis of new bitopic tetra(pyrazolyl)-ligands with neopentane and O-xylene backbones.

Potapov AS, Nudnova EA, Ogorodnikov VD, Petrenko TV, Khlebnikov AI.

ScientificWorldJournal. 2012;2012:798271. doi: 10.1100/2012/798271. Epub 2012 May 3.

28.

Identification and characterization of a novel class of c-Jun N-terminal kinase inhibitors.

Schepetkin IA, Kirpotina LN, Khlebnikov AI, Hanks TS, Kochetkova I, Pascual DW, Jutila MA, Quinn MT.

Mol Pharmacol. 2012 Jun;81(6):832-45. doi: 10.1124/mol.111.077446. Epub 2012 Mar 20.

29.

Synthesis and oxidation of some azole-containing thioethers.

Potapov AS, Chernova NP, Ogorodnikov VD, Petrenko TV, Khlebnikov AI.

Beilstein J Org Chem. 2011;7:1526-32. doi: 10.3762/bjoc.7.179. Epub 2011 Nov 16.

30.

Molecular docking of 2-(benzimidazol-2-ylthio)-N-phenylacetamide-derived small-molecule agonists of human formyl peptide receptor 1.

Khlebnikov AI, Schepetkin IA, Kirpotina LN, Brive L, Dahlgren C, Jutila MA, Quinn MT.

J Mol Model. 2012 Jun;18(6):2831-43. doi: 10.1007/s00894-011-1307-x. Epub 2011 Nov 30.

31.

Design, synthesis and evaluation of N-benzoylindazole derivatives and analogues as inhibitors of human neutrophil elastase.

Crocetti L, Giovannoni MP, Schepetkin IA, Quinn MT, Khlebnikov AI, Cilibrizzi A, Piaz VD, Graziano A, Vergelli C.

Bioorg Med Chem. 2011 Aug 1;19(15):4460-72. doi: 10.1016/j.bmc.2011.06.036. Epub 2011 Jul 7.

32.

Gastrin-releasing peptide/neuromedin B receptor antagonists PD176252, PD168368, and related analogs are potent agonists of human formyl-peptide receptors.

Schepetkin IA, Kirpotina LN, Khlebnikov AI, Jutila MA, Quinn MT.

Mol Pharmacol. 2011 Jan;79(1):77-90. doi: 10.1124/mol.110.068288. Epub 2010 Oct 13.

33.

Computational structure-activity relationship analysis of small-molecule agonists for human formyl peptide receptors.

Khlebnikov AI, Schepetkin IA, Quinn MT.

Eur J Med Chem. 2010 Nov;45(11):5406-19. doi: 10.1016/j.ejmech.2010.09.001. Epub 2010 Sep 15.

34.

Identification of novel small-molecule agonists for human formyl peptide receptors and pharmacophore models of their recognition.

Kirpotina LN, Khlebnikov AI, Schepetkin IA, Ye RD, Rabiet MJ, Jutila MA, Quinn MT.

Mol Pharmacol. 2010 Feb;77(2):159-70. doi: 10.1124/mol.109.060673. Epub 2009 Nov 10.

35.

Immunomodulatory activity of oenothein B isolated from Epilobium angustifolium.

Schepetkin IA, Kirpotina LN, Jakiw L, Khlebnikov AI, Blaskovich CL, Jutila MA, Quinn MT.

J Immunol. 2009 Nov 15;183(10):6754-66. doi: 10.4049/jimmunol.0901827. Epub 2009 Oct 21.

36.

Synthesis, characterization and potent superoxide dismutase-like activity of novel bis(pyrazole)-2,2'-bipyridyl mixed ligand copper(II) complexes.

Potapov AS, Nudnova EA, Domina GA, Kirpotina LN, Quinn MT, Khlebnikov AI, Schepetkin IA.

Dalton Trans. 2009 Jun 21;(23):4488-98. doi: 10.1039/b900869a. Epub 2009 Apr 7.

37.

Computational structure-activity relationship analysis of non-peptide inducers of macrophage tumor necrosis factor-alpha production.

Khlebnikov AI, Schepetkin IA, Kirpotina LN, Quinn MT.

Bioorg Med Chem. 2008 Oct 15;16(20):9302-12. doi: 10.1016/j.bmc.2008.08.078. Epub 2008 Sep 5.

38.

Identification of novel formyl peptide receptor-like 1 agonists that induce macrophage tumor necrosis factor alpha production.

Schepetkin IA, Kirpotina LN, Tian J, Khlebnikov AI, Ye RD, Quinn MT.

Mol Pharmacol. 2008 Aug;74(2):392-402. doi: 10.1124/mol.108.046946. Epub 2008 May 5.

39.

Structure-activity relationship analysis of N-benzoylpyrazoles for elastase inhibitory activity: a simplified approach using atom pair descriptors.

Khlebnikov AI, Schepetkin IA, Quinn MT.

Bioorg Med Chem. 2008 Mar 15;16(6):2791-802. doi: 10.1016/j.bmc.2008.01.014. Epub 2008 Jan 15.

40.

N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase.

Schepetkin IA, Khlebnikov AI, Quinn MT.

J Med Chem. 2007 Oct 4;50(20):4928-38. Epub 2007 Sep 12.

PMID:
17850059
41.

High-throughput screening for small-molecule activators of neutrophils: identification of novel N-formyl peptide receptor agonists.

Schepetkin IA, Kirpotina LN, Khlebnikov AI, Quinn MT.

Mol Pharmacol. 2007 Apr;71(4):1061-74. Epub 2007 Jan 17.

PMID:
17229869
42.

Improved quantitative structure-activity relationship models to predict antioxidant activity of flavonoids in chemical, enzymatic, and cellular systems.

Khlebnikov AI, Schepetkin IA, Domina NG, Kirpotina LN, Quinn MT.

Bioorg Med Chem. 2007 Feb 15;15(4):1749-70. Epub 2006 Nov 29.

43.

Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening.

Schepetkin IA, Khlebnikov AI, Kirpotina LN, Quinn MT.

J Med Chem. 2006 Aug 24;49(17):5232-44.

PMID:
16913712
44.

Quantitative structure-activity relationships for small non-peptide antagonists of CXCR2: indirect 3D approach using the frontal polygon method.

Khlebnikov AI, Schepetkin IA, Quinn MT.

Bioorg Med Chem. 2006 Jan 15;14(2):352-65. Epub 2005 Sep 22.

PMID:
16182534
45.

Characterization and biological activities of humic substances from mumie.

Schepetkin IA, Khlebnikov AI, Ah SY, Woo SB, Jeong CS, Klubachuk ON, Kwon BS.

J Agric Food Chem. 2003 Aug 27;51(18):5245-54.

PMID:
12926866

Supplemental Content

Loading ...
Support Center